Hengrui Pharma
Aggregated from S&P 500 earnings calls
Total Mentions
2
Companies
1
Sentiment
NEUTRAL 1
Mentions by Company
Merck & Co. Inc.Q3-2025
2×NEUTRAL
“$200 million for an upfront payment for a license agreement with Jiangsu Hengrui Pharmaceuticals Co., Ltd.”